Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)
ID: 351095Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351095

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-018.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Miniaturization and Automation of Tissue Chip Systems (MATChS)" aimed at U.S. small business concerns through STTR Phase I and II cooperative agreements. The initiative seeks to develop innovative microphysiological systems (MPS) that replicate human organ functions for drug discovery and biomedical research, addressing the limitations of traditional methods that are often costly and time-consuming. This funding opportunity is crucial for advancing tissue chip technology, enhancing the accessibility and usability of these systems in research, and supporting safe therapeutic assessments. Interested applicants can apply for a total funding commitment of up to $2.15 million, with key submission dates including an open date for applications on January 22, 2024, and a closing date of February 23, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-018.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-TR-23-018-Full-Announcement.html
    RFA-TR-23-018.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the Miniaturization and Automation of Tissue Chip Systems (MATChS) funding opportunity. This initiative invites U.S. small business concerns to submit applications for STTR Phase I and II cooperative agreements. The MATChS aims to develop innovative microphysiological systems (MPS) that mimic human organ functions for drug discovery and biomedical research, addressing challenges in traditional methods that are costly and time-consuming. Objectives include creating portable and automated MPS platforms with integrated sensors for high-throughput data analysis. The initiative builds upon previous collaborations between NIH, NCATS, and NASA, enhancing accessibility and usability of tissue chips in research. Key dates include an open date for submissions on January 22, 2024, and a funding commitment of up to $2.15 million for two Phase I awards and one Phase II award in FY 2024. The announcement emphasizes the need for milestone-driven projects with active NIH involvement in their development. Eligible applicants must be organized for profit, have a significant U.S. presence, and meet specific ownership and employee criteria. The MATChS serves to further the field of tissue chip technology, supporting safe and efficient therapeutic assessments while driving towards commercialization and practical application in clinical settings.
    Similar Opportunities
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Miniaturization and Automation of Tissue Chip Systems" (MATChS), aimed at advancing the development of automated and miniaturized microphysiological systems (MPS) for drug discovery and biomedical research. This funding opportunity encourages U.S. small business concerns (SBCs) to propose innovative solutions that enhance the efficiency and reliability of tissue chip technologies, with a focus on reducing complexity and costs while facilitating higher throughput. Approximately $2.15 million is allocated for FY 2024 to support projects that collaborate with NIH staff to achieve defined milestones and pathways to commercialization. Interested applicants must submit their proposals by February 23, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Tissue Chips in Space 2.0: Translational Multi-Organ Tissue Chip Systems for Drug Efficacy, Toxicity Testing, and Personalized Medicine in Human Health, Aging and Associated Diseases (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Tissue Chips in Space 2.0," aimed at developing multi-organ microphysiological systems (MPS) to study the effects of microgravity on human health, particularly in relation to aging and associated diseases. This initiative seeks to advance biomedical research by creating automated MPS technologies that replicate human organ functions, with the goal of assessing drug efficacy and safety in low Earth orbit at the International Space Station. The total funding commitment for this project is $5.6 million, and eligible applicants include a diverse range of organizations, such as historically black colleges and universities, tribal colleges, and faith-based organizations. Interested parties should note that the application deadline is October 18, 2024, and can find more information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) Grant Applications, inviting eligible U.S. small businesses to submit proposals for innovative projects that align with NIH's research and development mission. This funding opportunity, identified as PA-24-247, specifically excludes clinical trials and aims to foster collaboration between small businesses and research institutions to advance technology development in health-related fields. Eligible applicants must be for-profit small businesses based in the U.S., with budget limits set at $306,872 for Phase I and $2,045,816 for Phase II awards. The application deadline is April 5, 2025, with an initial submission date of September 5, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) grant applications, inviting eligible U.S. small businesses to submit proposals that include at least one clinical trial. This funding opportunity aims to support research and development projects that align with the scientific missions of participating NIH Institutes and Centers, emphasizing the importance of innovation in health-related technologies. Eligible applicants must be U.S.-based small businesses with majority ownership by U.S. citizens or resident aliens, and the grants provide funding caps of up to $306,872 for Phase I and $2,045,816 for Phase II projects. Interested parties should note that the application deadline is April 5, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Small Business Technology Transfer (STTR) grants titled "Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models." This initiative aims to encourage small businesses to develop innovative tools and devices that enhance the welfare and management of laboratory animals, thereby improving the reproducibility of biomedical research experiments. The funding is particularly focused on projects that design and implement technologies for monitoring environmental conditions and managing animal care efficiently, addressing critical challenges in animal research facilities. Interested applicants can apply for Phase I grants with a maximum budget of $259,613 and Phase II grants up to $1,730,751, with a project period of up to two years for Phase II. The application deadline is January 6, 2025, and further details can be obtained by contacting the NIH OER Webmaster at grantsinfo@nih.gov or visiting the funding announcement page at http://grants.nih.gov/grants/guide/pa-files/PAR-21-226.html.
    Research Resource for Human Organs and Tissues (U42 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Resource for Human Organs and Tissues" through a cooperative agreement mechanism (U42), aimed at supporting a program that provides and facilitates the availability of human tissues and organs for biomedical research. The initiative seeks to enhance the procurement, preservation, and distribution of diverse biospecimens, both normal and diseased, to aid researchers in understanding various diseases and addressing public health priorities. Applicants must demonstrate a proven track record in managing a human tissue and organ research resource, with direct costs capped at $720,000 over a potential five-year project period. The application period opens on December 24, 2024, with a submission deadline of September 25, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small businesses to develop novel extracellular vesicle (EV)-based therapeutic platforms aimed at regenerative medicine through a cooperative agreement. The primary objective is to support the production, manufacturing, and application of EVs for tissue and organ repair, with a focus on utilizing stem cells for EV generation and ensuring GMP-compliant production. This initiative is critical for advancing therapeutic technologies in regenerative medicine, with funding amounts capped at $295,924 for Phase I and $1,972,828 for Phase II grants, while clinical trials are not permitted under this opportunity. Interested applicants must adhere to strict submission guidelines and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, with the application deadline set for June 6, 2025.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) to develop extracellular vesicle (EV)-based therapeutic platforms aimed at regenerative medicine. The primary objective of this funding opportunity announcement (FOA) is to support the production and manufacturing of both native and engineered EVs for tissue and organ repair, with applications focusing on feasibility and initial proof of concept in Phase I, and optimization and scaling in Phase II. This initiative is crucial for advancing regenerative medicine technologies and addressing challenges in EV therapeutics, ultimately facilitating their application in clinical settings. Eligible applicants can receive funding up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by June 6, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-268.html.
    PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), has announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) Grant Applications. This funding opportunity invites eligible U.S. small businesses to submit applications for Phase I, Phase II, Fast-Track, and Direct to Phase II projects that align with the research missions of the NIH, CDC, and FDA, with a focus on stimulating technological innovation and commercialization of federal R&D investments. Notably, applications must not include clinical trials, and funding levels are capped at $306,872 for Phase I and up to $2,045,816 for Phase II, with a submission deadline of April 5, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 grant mechanism to support the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate the architectures and functions of the human nervous system. This initiative aims to encourage high-risk, high-reward exploratory research, particularly relevant for addressing complex nervous system disorders, and is open to a diverse range of eligible applicants, including educational institutions, non-profits, and governmental entities. The funding, capped at $275,000 over a two-year period, emphasizes collaboration among experts in neurobiology, engineering, and ethics, and applications must adhere to NIH data management and sharing policies. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 7, 2026.